Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide

Mougiakakos D, Völkl S, Bach C, Stoll A, Bitterer K, Beier F, Endell J, Boxhammer R, Bittenbring JT, Mackensen A, Bruns H (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Blood American Society of Hematology

Publisher: AMER SOC HEMATOLOGY

City/Town: WASHINGTON

Conference Proceedings Title: BLOOD

Event location: Orlando, FL

DOI: 10.1182/blood-2019-124886

Authors with CRIS profile

Dimitrios Mougiakakos Professur für Hämatologie/Onkologie mit dem Schwerpunkt Tumorimmunologie Simon Völkl Department of Medicine 5 – Haematology and Oncology Christian Bach Department of Medicine 5 – Haematology and Oncology Andreas Mackensen Lehrstuhl für Innere Medizin V Heiko Bruns Department of Medicine 5 – Haematology and Oncology

Involved external institutions

Universitätsklinikum Aachen (UKA) DE Germany (DE) Universität des Saarlandes (UdS) DE Germany (DE) MorphoSys AG DE Germany (DE)

How to cite

APA:

Mougiakakos, D., Völkl, S., Bach, C., Stoll, A., Bitterer, K., Beier, F.,... Bruns, H. (2019). Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide. In BLOOD. Orlando, FL: WASHINGTON: AMER SOC HEMATOLOGY.

MLA:

Mougiakakos, Dimitrios, et al. "Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide." Proceedings of the 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL WASHINGTON: AMER SOC HEMATOLOGY, 2019.

BibTeX: Download